Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,713 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.
Luke JJ, Barlesi F, Chung K, Tolcher AW, Kelly K, Hollebecque A, Le Tourneau C, Subbiah V, Tsai F, Kao S, Cassier PA, Khasraw M, Kindler HL, Fang H, Fan F, Allaire K, Patel M, Ye S, Chao DT, Henner WR, Hayflick JS, McDevitt MA, Fong L. Luke JJ, et al. Among authors: kao s. J Immunother Cancer. 2021 Feb;9(2):e002015. doi: 10.1136/jitc-2020-002015. J Immunother Cancer. 2021. PMID: 33608377 Free PMC article. Clinical Trial.
A tailored approach to horizon scanning for cancer medicines.
Soon JA, To YH, Alexander M, Trapani K, Ascierto PA, Athan S, Brown MP, Burge M, Haydon A, Hughes B, Itchins M, John T, Kao S, Koopman M, Li BT, Long GV, Loree JM, Markman B, Meniawy TM, Menzies AM, Nott L, Pavlakis N, Petrella TM, Popat S, Tie J, Xu W, Yip D, Zalcberg J, Solomon BJ, Gibbs P, McArthur GA, Franchini F, IJzerman M. Soon JA, et al. Among authors: kao s. J Cancer Policy. 2023 Dec;38:100441. doi: 10.1016/j.jcpo.2023.100441. Epub 2023 Nov 20. J Cancer Policy. 2023. PMID: 38008488 Free article.
COVID-19: the use of immunotherapy in metastatic lung cancer.
Davis AP, Boyer M, Lee JH, Kao SC. Davis AP, et al. Immunotherapy. 2020 Jun;12(8):545-548. doi: 10.2217/imt-2020-0096. Epub 2020 Apr 30. Immunotherapy. 2020. PMID: 32349579 Free PMC article. No abstract available.
A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases.
Itchins M, Ainsworth H, Alexander M, Dean S, Dharmaraj D, Pavlakis N, Clarke SJ, Brown C, Torres J, Saqib A, Ladwa R, O'Byrne K, Moore M, Yip PY, Solomon B, John T, Kao S, Mitchell P, Parakh S. Itchins M, et al. Among authors: kao s. Clin Lung Cancer. 2022 Dec;23(8):702-708. doi: 10.1016/j.cllc.2022.07.016. Epub 2022 Aug 7. Clin Lung Cancer. 2022. PMID: 36030187
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE.
Tan L, Brown C, Mersiades A, Lee CK, John T, Kao S, Newnham G, O'Byrne K, Parakh S, Bray V, Jasas K, Yip S, Wong SQ, Ftouni S, Guinto J, Chandrashekar S, Clarke S, Pavlakis N, Stockler MR, Dawson SJ, Solomon BJ. Tan L, et al. Among authors: kao s. Nat Commun. 2024 Feb 28;15(1):1823. doi: 10.1038/s41467-024-46008-1. Nat Commun. 2024. PMID: 38418463 Free PMC article. Clinical Trial.
1,713 results